Table 1.
Baseline demographic characteristics (N = 165)
| Clinical characteristic | Values* |
|---|---|
| Age, years | 56.2 (44.1–66.4) |
| Gender (% F) | 83.6 |
| Swollen joint count | 3 (2–8) |
| Tender joint count | 9 (3–18) |
| CDAI | 22.0 (12.5–34.0) |
| CRP (mg/L) | 3.3 (1.0–10.2) |
| Disease duration, years | 4.6 (1.4–16.4) |
| PROMIS Global Health Pain Numeric Rating Score | 5.2 (2.3) |
| Pain Catastrophizing Scale Score | 16 (8–28) |
| PROMIS Depression Score | 49.9 (45.7–56.5) |
| PROMIS Anxiety Score | 54.0 (8.6) |
| Patient Global Assessment Score | 40.2 (23.1) |
| Assessor Global Score | 30 (20–50) |
| DMARD use (in the past 6 weeks, %) | 58.8 |
| Non-biological DMARD use (in the past 6 weeks, %) | 43.0 |
| Biological DMARD use (in the past 6 weeks, %) | 24.2 |
*
Numbers in parentheses correspond to median (25th-75th percentile) or mean (standard deviation). TNF = tumor necrosis factor. DMARD = disease-modifying antirheumatic drug. In the 6 weeks prior to study, some patients were on both biological and non-biological DMARDs.